AgingResearch.NewsJoin free

Mirabegron

Mirabegron has been studied in 14 papers since 2016: 2 trials and 7 observational studies in people, 1 in cells, 2 reviews; 4 in the past year. It is an approved medicine. The newest story, Nov 6, 2026: “Bladder drugs presumed safer not linked to lower dementia risk”.

InterventionApproved 2012

14 papers study it8 more mention it12 findingsUpdated

PubChemChEBIMeSH

4 new papers in 30 daysSee all 22 papers on mirabegron

At a glance

The findings reach people, from one lab or study. 4 independent labs in 3 countries; 120 trials, none about aging, 49 with no results posted.

“Mirabegron significantly improved in total score of the OABSS, including urgency and urge incontinence.”
Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)BMC urology2022doi:10.1186/s12894-022-00989-7

1 of its findings points the other way.

Cells and humans: a single group. Worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

About aging: the drug’s trials about aging. The total counts its trials for every use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

  • 4 independent labs in 3 countries
  • 1 finding against
  • 120 trials, none about aging, 49 with no results posted
  • Funders: Claude D. Pepper Older Americans Independence Center and 3 more
  • 61 of 120 trials sponsored by its developers
  • Human trial2
  • Humans7
  • Cells1

Studies in people

2 studies gave mirabegron to people and measured what changed.

What changedDesignPeopleSource

up: Improves overactive bladder symptoms−3.8 points

up: Improves quality of life

down: Decreases frailty

Trial12-week43 people15 females (35%) and 28 males (65%)median 84 y/o (range: 80–96 y/o)Patients aged ≥ 80 years with persistent overactive bladder symptoms after behavioral therapyBMC urology, Mar 21, 2022

up: Improves cognitive function

down: Decreases neurogenic lower urinary tract dysfunction

no change: Has no effect on heart rate

Trial6 months20 people>60 y/oOlder adults; neurogenic lower urinary tract dysfunction in older persons with spinal cord injury switched from anticholinergicsSpinal cord series and cases, Jun 10, 2021

What did studies of mirabegron find?

9

Studies of mirabegron measured 9 outcomes; the most studied are cognitive function (2 studies), overactive bladder symptoms (1) and obesity-related neoplasms (1).

Cognitive function

no changein humans1upin humans1

2 studies

  1. Mirabegron showed no clear effect on cognitive function in humans.

    “There was no deterioration in the mean MMSE score at 4, 8, or 12 weeks compared with the baseline.”

    Human trial12-weekn = 43

    Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)

    BMC urology

  2. Mirabegron improves cognitive function in humans.

    “older persons with SCI exhibited statistically significant improvements in immediate Story A recall (p = 0.01), delayed story A and B recall (p = 0.01, 0.004), and in TEXAS (p = 0.04).”

    Human trialneurogenic lower urinary tract dysfunction in older persons with spinal cord injury switched from anticholinergics6 monthsn = 20

    The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: An open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy

    Spinal cord series and cases

Overactive bladder symptoms

upin humans1

1 study

  1. Mirabegron improves overactive bladder symptoms in humans (−3.8 points).

    “Significant improvements from the baseline were seen in the total OABSS score at 4, 8, and 12 weeks.”

    Human trial12-weekn = 43

    Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)

    BMC urology

  2. Mirabegron improves overactive bladder symptoms in humans (overactive bladder).

    “Mirabegron significantly improved in total score of the OABSS, including urgency and urge incontinence.”

    Human trialoveractive bladder50 mg once daily12 weeksn = 43

    Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)

    BMC urology

Obesity-related neoplasms

no changein humans1HR 1.011

1 study

  1. Mirabegron was not clearly linked with obesity-related neoplasms in humans (HR 1.011, 95% CI 0.954–1.071).

    “Mirabegron initiation was not associated with the composite of obesity-related neoplasms compared with antimuscarinic initiation (HR, 1.011; 95% CI, 0.954-1.071).”

    HumansPatients with overactive bladder; mirabegron initiation compared with antimuscarinic initiation after a 1-year landmark period

    Comparative Neoplasm Risk of Mirabegron and Antimuscarinic Therapy in Overactive Bladder: A Multicenter Target Trial Emulation

    Cancers

More on Obesity-related neoplasms

Aβ efflux

downin human cells1

1 study

  1. Mirabegron inhibits Aβ efflux in vitro endothelial vessel wall models.

    “mirabegron inhibited it”

    Cellsin vitro endothelial vessel wall models

    Impact of P-glycoprotein substrates on transendothelial transport of amyloid-β peptide in an in vitro model

    Neuroscience

More on Aβ efflux

Frailty

downin humans1

1 study

  1. Mirabegron decreases frailty in humans.

    “Regarding frailty, there was significant improvement in the VES-13 score between the baseline and 8 or 12 weeks, though no change between the baseline and 4 weeks.”

    Human trial12-weekn = 43

    Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)

    BMC urology

Quality of life

upin humans1

1 study

  1. Mirabegron improves quality of life in humans.

    “Regarding QOL, OAB-q symptom bother and OAB-q total health-related QOL (HRQL) scores were significantly improved at 8 and 12 weeks.”

    Human trial12-weekn = 43

    Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)

    BMC urology

Heart rate

no changein humans1

1 study

  1. Mirabegron showed no clear effect on heart rate in humans (older persons with spinal cord injury switched from anticholinergics).

    “NBD, HR, MAP, and EKGs were unchanged.”

    Human trialolder persons with spinal cord injury switched from anticholinergics6 monthsn = 20

    The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: An open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy

    Spinal cord series and cases

More on Heart rate

Neurogenic lower urinary tract dysfunction

downin humans1

1 study

  1. Mirabegron decreases neurogenic lower urinary tract dysfunction in humans.

    “Three subscores within NBSS significantly improved (p = 0.001) and the frequency of incontinence decreased (p = 0.03) on mirabegron.”

    Human trialneurogenic lower urinary tract dysfunction in older persons with spinal cord injury switched from anticholinergics6 monthsn = 20

    The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: An open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy

    Spinal cord series and cases

More on Neurogenic lower urinary tract dysfunction

Morphological changes of the bladder

downin reviews1

1 study

  1. Mirabegron protects against morphological changes of the bladder in experimental models of pelvic arterial insufficiency/ischemia.

    “exerted a protecting effect on urodynamic parameters, and on functional and morphological changes of the bladder demonstrable in vitro.”

    Reviewin experimental models of pelvic arterial insufficiency/ischemia

    The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction

    Therapeutic advances in urology

What is mirabegron linked with?

1

Studies link mirabegron with 1 measure, most often mortality (1 study).

Mortality

upin humans1HR 1.083

1 study

  1. Mirabegron is associated with mortality in humans (HR 1.083, 95% CI 1.044–1.124).

    “mirabegron initiation was associated with higher subsequent all-cause mortality (HR, 1.083; 95% CI, 1.044-1.124).”

    HumansPatients with overactive bladder eligible for the 1-year landmark mortality analysis; compared with antimuscarinic initiation

    Comparative Neoplasm Risk of Mirabegron and Antimuscarinic Therapy in Overactive Bladder: A Multicenter Target Trial Emulation

    Cancers

Has mirabegron been tested in people?

0 of 120 about aging

Yes: 2 trials and 7 observational studies in people have been published, and 120 trials are registered.

Approved

  • FDA Myrbetriq

    Jun 28, 2012Urinary Incontinence, Urge, overactive bladder, urinary frequency, neurogenic detrusor overactivity

  • EMA Betmiga

    Dec 20, 2012Urinary Bladder, Overactive, Overactive Bladder Syndrome, overactive bladder, incontinence, neurogenic detrusor overactivity

  • FDA Myrbetriq Granules

    Mar 25, 2021Urinary Incontinence, Urge, overactive bladder, urinary frequency, neurogenic detrusor overactivity

Repurposing

All 39

In trials

  • Pharmacokinetic of mirabegron

    Phase 4Results posted9 trials

  • Cognition disorder

    Phase 4Results posted1 trial

  • Food effect

    Phase 4Results posted1 trial

  • Pharmacokinetic of mirabegron and tolterodine

    Phase 4Completed1 trial

  • Neurogenic Urinary Bladder

    Phase 2/3Terminated3 trials

  • Ovarian cancer recurrent

    Phase 2/3Recruiting1 trial

All 21

Readouts due

Stopped

  • NCT02787083TerminatedInterstitial cystitis

    Low enrollment

  • NCT02044510TerminatedSpinal cord injury

    Slow recruitment and small observed effect size

  • NCT02462837TerminatedPain

    insufficient rate of accrual

  • NCT03411252TerminatedEsophageal achalasia

    inability to enroll

Who is developing mirabegron?

3 companies: Astellas Pharma Global Development, Astellas Pharma and Astellas Pharma China.

Companies
  • Astellas Pharma Global DevelopmentPhase 4overactive bladder, benign prostatic hyperplasia
  • Astellas PharmaPhase 4overactive bladder, overactive urinary bladder
  • Astellas Pharma ChinaPhase 4urge incontinence, overactive bladder

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 2Nov 2026: 16 papers in 12 months
JAMA Network Open

Bladder drugs presumed safer not linked to lower dementia risk

Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.

Cohort · 830,393 peopleIncident dementia
Paper

See all 22 papers on mirabegron

Related